Jennifer Mooi

1.1k total citations
21 papers, 471 citations indexed

About

Jennifer Mooi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jennifer Mooi has authored 21 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Jennifer Mooi's work include Colorectal Cancer Treatments and Studies (8 papers), Genetic factors in colorectal cancer (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jennifer Mooi is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Genetic factors in colorectal cancer (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jennifer Mooi collaborates with scholars based in Australia, United States and Switzerland. Jennifer Mooi's co-authors include Sabe Sabesan, Lisa J Whop, Patricia C. Valery, John M. Mariadason, Niall C. Tebbutt, Timothy Price, Shankar Siva, Nathan Lawrentschuk, Peter Savas and Michael T.M. Wang and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Jennifer Mooi

21 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Mooi Australia	9	216	185	110	107	93	21	471
Kelsey L. Corrigan United States	12	296 1.4×	97 0.5×	93 0.8×	46 0.4×	98 1.1×	52	585
Toufic Eid Lebanon	11	279 1.3×	87 0.5×	62 0.6×	131 1.2×	44 0.5×	20	520
S. Jezdic Italy	9	316 1.5×	233 1.3×	144 1.3×	319 3.0×	85 0.9×	15	795
Pedro De Marchi Brazil	11	277 1.3×	245 1.3×	109 1.0×	115 1.1×	61 0.7×	57	514
Atara Ntekim Nigeria	12	198 0.9×	129 0.7×	152 1.4×	137 1.3×	44 0.5×	48	536
Tsutomu Kouno Japan	12	241 1.1×	96 0.5×	63 0.6×	108 1.0×	110 1.2×	31	432
Molly Gabel United States	11	265 1.2×	97 0.5×	45 0.4×	143 1.3×	54 0.6×	17	480
Sebastian Belle Germany	17	455 2.1×	219 1.2×	206 1.9×	153 1.4×	255 2.7×	65	852
Gunta Purkalne Latvia	12	183 0.8×	119 0.6×	151 1.4×	129 1.2×	49 0.5×	31	425
J.J. Grau Spain	9	312 1.4×	216 1.2×	112 1.0×	71 0.7×	152 1.6×	14	543

Countries citing papers authored by Jennifer Mooi

Since Specialization

Citations

This map shows the geographic impact of Jennifer Mooi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Mooi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Mooi more than expected).

Fields of papers citing papers by Jennifer Mooi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Mooi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Mooi. The network helps show where Jennifer Mooi may publish in the future.

Co-authorship network of co-authors of Jennifer Mooi

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Mooi. A scholar is included among the top collaborators of Jennifer Mooi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Mooi. Jennifer Mooi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tacey, Mark, et al.. (2024). Addressing disparities in health outcomes for patients with advanced pancreatic cancer and limited English proficiency. Asia-Pacific Journal of Clinical Oncology. 20(4). 531–536. 1 indexed citations

Esmaeilniakooshkghazi, Amin, Sudeep P. George, Srinivas Patnaik, et al.. (2023). In colon cancer cells fascin1 regulates adherens junction remodeling. The FASEB Journal. 37(3). e22786–e22786. 3 indexed citations

Ali, Muhammad, Jennifer Mooi, Nathan Lawrentschuk, et al.. (2022). The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. European Urology. 82(6). 613–622. 51 indexed citations

Chionh, Fiona, Val Gebski, Sheren Al-Obaidi, et al.. (2022). VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports. 12(1). 1238–1238. 12 indexed citations

Dijk, Erik van, Erik van Werkhoven, Rebecca Asher, et al.. (2022). Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX. International Journal of Cancer. 151(7). 1166–1174. 2 indexed citations

Mooi, Jennifer, Fiona Chionh, Peter Savas, et al.. (2021). Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research. 27(8). 2159–2167. 12 indexed citations

Pryor, David, Mathias Bressel, Nathan Lawrentschuk, et al.. (2021). A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemporary Clinical Trials Communications. 21. 100703–100703. 7 indexed citations

Siva, Shankar, Mathias Bressel, Simon Wood, et al.. (2021). Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. European Urology. 81(4). 364–372. 84 indexed citations

Siva, Shankar, Mathias Bressel, Sherene Loi, et al.. (2019). MA01.01 Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases. Journal of Thoracic Oncology. 14(10). S248–S248. 2 indexed citations

10.

Siva, Shankar, Mathias Bressel, Shahneen Sandhu, et al.. (2019). OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC. Radiotherapy and Oncology. 133. S137–S137. 1 indexed citations

11.

Mooi, Jennifer, Pratyaksha Wirapati, Rebecca Asher, et al.. (2018). The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Annals of Oncology. 29(11). 2240–2246. 99 indexed citations

12.

Mooi, Jennifer, Ian Y. Luk, & John M. Mariadason. (2018). Cell Line Models of Molecular Subtypes of Colorectal Cancer. Methods in molecular biology. 1765. 3–26. 8 indexed citations

13.

Tay, Rebecca, Fiona Chionh, Jennifer Mooi, et al.. (2018). Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. British Journal of Cancer. 118(7). 966–971. 35 indexed citations

14.

Lee, Belinda, Ben Tran, Arthur Hsu, et al.. (2018). Exploring the feasibility and utility of exome‐scale tumour sequencing in a clinical setting. Internal Medicine Journal. 48(7). 786–794. 3 indexed citations

15.

Sandhu, Shahneen, John Violet, Justin Ferdinandus, et al.. (2018). Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. Journal of Clinical Oncology. 36(15_suppl). 5040–5040. 1 indexed citations

16.

Mooi, Jennifer, et al.. (2017). Minimising instilled volume reduces the impact of fluorescein on clinical measurements of tear film stability. Contact Lens and Anterior Eye. 40(3). 170–174. 42 indexed citations

17.

Mooi, Jennifer, Pratyaksha Wirapati, Rebecca Asher, et al.. (2017). Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial. Annals of Oncology. 28. v160–v161. 1 indexed citations

18.

Mooi, Jennifer, Geoffrey Chong, Stephen Brown, et al.. (2015). Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.. Journal of Clinical Oncology. 33(15_suppl). 3533–3533. 1 indexed citations

19.

Mooi, Jennifer, Lisa J Whop, Patricia C. Valery, & Sabe Sabesan. (2012). Teleoncology for Indigenous patients: The responses of patients and health workers. Australian Journal of Rural Health. 20(5). 265–269. 71 indexed citations

20.

Otty, Zulfiquer, et al.. (2011). Efficacy and tolerability of weekly low‐dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia-Pacific Journal of Clinical Oncology. 7(3). 287–292. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact